Palatin Technologies, Inc. (NYSEMKT:PTN) stock market valuation has zoomed upwards by a 15.1 percent post the announcement by the small capped biopharmaceutical firm on 31st March after it agreed to extend the term of a ‘in force option’ it had previously entered into with a prospective partner by further 30 days. Palatin Technologies, Inc. (NYSEMKT:PTN) shares after opening at $1.17 moved to $1.30 on last trade day and at the end of the day closed at $1.25. Company price to cash ratio in past twelve months was calculated as 2.70.
IsoRay, Inc. (NYSEMKT:ISR) announced the first prostate cancer implant combining IsoRay’s Cesium-131 seeds with C4 Imaging’s Sirius positive signal MRI markers. IsoRay CEO Dwight Babcock commented, “We are very excited to have our Cesium-131 isotope seeds chosen to partner with C4 Imaging’s innovative positive signal MRI markers in the treatment of prostate cancer. IsoRay, Inc. (NYSEMKT:ISR) shares advanced 5.26% in last trading session and ended the day on $2.80. ISR return on equity ratio is recorded as -71.90% and its return on assets is -56.60%. Palatin Technologies, Inc. (NYSEMKT:PTN) yearly performance is 428.30%.
BioLife Solutions (NASDAQ:BLFS)‘s stock had its “outperform” rating reaffirmed by Zacks in a research note issued to investors on Friday,Analyst Ratings Network.com reports. BioLife Solutions Inc (NASDAQ:BLFS) shares moved up 9.97% in last trading session and was closed at $3.64 while trading in range of $3.30 – $3.80 – BioLife Solutions Inc (NASDAQ:BLFS) year to date (YTD) performance is -56.67%.
Oramed Pharmaceuticals (NASDAQ:ORMP) Director Michael Berelowitz sold 9,434 shares of the company’s stock on the open market in a transaction dated Monday, March 31st. The shares were sold at an average price of $10.50, for a total value of $99,057.00. Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) weekly performance is 18.09%. On last trading day company shares ended up $13.84. Analysts mean target price for the company is $31.00.